The concept of ursodeoxycholic acid continued to skyrocket, and Xintai Pharmaceutical, Xinhua Pharmaceutical, etc. rose to the limit

News on December 8, the concept of ursodeoxycholic acid continues to skyrocket, from the perspective of individual stocks, Xuantai Pharmaceutical, Xinhua Pharmaceutical, Qianhong Pharmaceutical, etc.
are all up and down, of which Xuantai Pharmaceutical, Xinhua Pharmaceutical has gained two consecutive boards, in addition, Common Pharmaceutical rose by more than 14%.

On the news, on December 5, 2022, researchers at the University of Cambridge in the United Kingdom published a research paper in the journal "Nature", which mentioned a drug for the treatment of liver disease, ursodeoxycholic acid (UDCA).

Affected by this news, many concept stocks including United Pharmaceutical, Sinotherapeutics and so on on December 7 both rose to the limit
.
As of 10:30 on December 8, Sinotherapeutics rose by nearly 20%, with a quotation of 16.
63 yuan, a turnover of 328 million, and a turnover rate of 48.
67%.

On the news, Sinotherapeutics recently said on the investor interactive platform that the company's ursodeoxycholic acid capsule products will be commercially supplied
in the near future.
As of 10:30, Mutual Pharmaceutical rose by more than 11%, with a quotation of 34.
81 yuan, a turnover of 628 million, and a turnover rate of 30.
61%.

The company's main business is the research and development, production and sales of steroidal drug starting materials and intermediates, and the main products are the starting materials and intermediates
required for the production of steroid drugs.
On November 22, 2022, it was announced that the company's fundraising products will replace the market share
of traditional process route products such as "saponin-diene-progesterone" and animal-derived ursodeoxycholic acid.
However, the company said on the interactive platform on December 7 that the company has not had business dealings with Sinotherapeutics; Whether downstream customers use bis-desceptol to produce ursodeoxycholic acid-related drugs, it is not yet understood, the extension of didownhol downstream can produce different products according to different processes, and the actual needs of downstream customers shall prevail
.
As of 10:30, Xinhua Pharmaceutical rose 10%, with a quotation of 29.
66 yuan, a turnover of 2.
396 billion yuan, and a turnover rate of 18.
69%.

According to the analysis, the reasons for the change include: the company is mainly engaged in the development, manufacture and sales of chemical APIs, preparations and chemical products, the main products are antipyretic and analgesic APIs, tablets, injections, capsules, pharmaceutical intermediates; The company is an important manufacturer of antipyretic and analgesic APIs in the world, including ibuprofen, aspirin, metamizole sodium, aminopyrine, antipyrine, ipproantipyrine, tramadol, meloxicam and other varieties
.
In addition, the company signed a strategic cooperation agreement with Real Biologics, and Real Biologics agreed that Xinhua Pharmaceutical is the manufacturer and distributor
of azvudine and other products owned by Xinhua Pharmaceutical in China and other countries agreed by both parties.
As of 10:30, Qianhong Pharmaceutical rose by more than 7%, with a quotation of 7.
15 yuan, a turnover of 1.
265 billion yuan, and a turnover rate of 18.
97%.

The stock has risen 14 times
in the past year.
The company's main business is the research and development, production and sales
of lyophilized powder, lyophilized powder injection (including anti-tumor drugs), small volume injection (non-final sterilization), tablets, hard capsules, granules and APIs within the scope of drug production license.
The company has 46 specifications including tablets, hard capsules, lyophilized powder and lyophilized powder injections, small volume injections and APIs
.
It is reported that the company's production of ursodeoxycholic acid tablets has begun to sell
.
Looking forward to the future market, the pharmaceutical sector is generally optimistic
about the industry.
CITIC Securities Research Report said that combined with the main tone of common prosperity, the direction and trend of medical reform of deep change have gradually become clear, and in 2023, in the environment of gradually clear policy expectations and gradual stabilization of the domestic and foreign political environment, combined with the current low valuation of the sector, the focus is on the bottoming and rebound opportunities
of the biomedical sector.
Caixin Securities also believes that the current long-term bottom in the market has been confirmed, under the resonance of capital and policy, the growth sector that is expected to improve marginally next year will achieve excess returns, and it is recommended to pay attention to the biomedical sector
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.